CompoAtlas

NicoDerm 14 mg

Produit de santé naturel homologué au Canada

Titulaire
Kenvue Canada Inc.
NPN ou DIN-HM
02093138
Statut
Licence active
Date de licence
19 novembre 2007
Date de révision
26 juillet 2024
Forme
Timbre transdermique
Voie d'administration
Transdermique
Type de demande
Non traditionnelle

L’analyse des doses orales ne s’applique pas sans voie exclusivement orale établie.

Composition

Composition médicinale non renseignée.

Ingrédients non médicinaux

Siliconized polyester film, High density polyethylene film, Polyisobutylene, Ethylene-vinyl acetate copolymer

Doses recommandées au Canada

PopulationÂgeQuantité par priseFréquence
AdultesNon précisée1 patch1 Tous les jours

Usages autorisés au Canada

Texte fourni en anglais, faute de texte français disponible.

NICODERM(R) 14 mg Step 2 patch is a medicine that can help you stop smoking by reducing withdrawal symptoms and nicotine cravings. NICODERM(R) is a form of nicotine replacement therapy (NRT) that can help double your chances of quitting successfully. NICODERM(R) provides a lower level of nicotine to your blood than cigarettes, and allows you to gradually do away with your body's need for nicotine. It works as a temporary aid to help you quit smoking by reducing nicotine cravings and nicotine withdrawal symptoms such as irritability, frustration, anxiety, difficulty concentrating and restlessness. Without these powerful urges for the cigarettes you "need", getting rid of the "habit" cigarettes becomes much easier. The good news is that NICODERM(R) contains no tar or carbon monoxide, and therefore doesn't present the same medical risks as cigarettes. NICODERM(R) provides 24 hour rate-controlled delivery of nicotine following its application to intact skin. NICODERM(R) reduces the withdrawal symptoms associated with smoking cessation and thus increases the success rate of smoking cessation programs. NICODERM(R) is the only patch that has a rate controlling membrane, to give your body a steady supply of nicotine to help protect you against cravings. Following the first NICODERM(R) application, the plasma nicotine concentration rises rapidly, plateaus within 2 to 4 hours and then slowly declines until the system is removed; after which it declines more rapidly. Nicotine in the adhesive layer is absorbed into and through the skin, causing the initial rapid rise in plasma concentration. The nicotine from the reservoir is released slowly through the membrane with a constant release rate. The rate of release of nicotine from the NICODERM(R) 14 mg/24 hour patch is 1.0 mg/hr. Following the second daily NICODERM(R) system application, steady state plasma nicotine concentration is achieved and is on average 30% higher compared with single dose applications. The quit rate for NICODERM(R) 14 mg/day was 54%. The unique feature offers 24-hour protection, even against the early morning cravings many people find the most difficult. Combination Nicotine Replacement Therapy - Nicoderm(R) patch + as needed Nicorette(R) gum/lozenge/oral inhaler/ oral mist versus mono Nicotine Replacement Therapy is: - Clinically proven to increase your chances of quitting. - A clinically proven approach to increase your chances of quitting for good. -If you have a relapse or experience tough/intense cravings or failed with the patch alone, you can use the patch with as needed Nicorette(R) gum/lozenge/oral inhaler/oral mist at the same time to increase your chances of quit success. - Now you can have the combined support of NICODERM(R) patch and NICORETTE(R) as needed gum/lozenge, oral inhaler/ oral mist products together, for a successful quit. - Tackle cravings: NICODERM(R) (patch) for slow release constant support and NICORETTE(R) as needed (gum/lozenge, oral inhaler/ oral mist) for an extra quick fix/dose when you really need to fight back the cravings / when something triggers intense cravings. - Combination therapy is 30%/1.3x more effective than using one Nicotine Replacement Therapy product alone. - Use NICODERM® patch + NICORETTE® (gum/lozenge/inhaler/oral mist) together to increase your chance of quitting.

Un usage autorisé au Canada n'est pas une allégation de santé autorisée dans l'Union européenne. Consultez le registre des allégations de santé.

Mises en garde au Canada

Aucun texte de mise en garde en français disponible dans les données importées.

Des mises en garde sont disponibles en anglais sur la fiche officielle.

Source

Fiche officielle Santé Canada, licence 02093138

Base de données des produits de santé naturels homologués (BDPSNH), Santé Canada : produits homologués, ingrédients, doses, usages et mises en garde, consulté le 27 octobre 2026.

Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPSNH)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

La formule vendue en Europe sous le même nom peut être différente. Ces informations ne remplacent pas l'avis d'un médecin ou d'un pharmacien.

Liste dans la révision officielle du (registre Base de données des produits de santé naturels homologués (BDPSNH), Santé Canada : produits homologués, ingrédients, doses, usages et mises en garde).

Liste relevée en 2024. Photographiez l’emballage pour vérifier qu’elle n’a pas changé. Photographier l’emballage

Liste relevée en 2024. Photographiez l’emballage pour vérifier qu’elle n’a pas changé.

Entrée pour analyser, Maj+Entrée pour une nouvelle ligne